Case reports of Campanacci grade II and III distal ulna giant cell tumour of bone in the previous 10 years
| Author | Year | Journal | Age/Sex | Campanacci | Treatment | Reconstruction | Recurrence | Wrist function | Denosumab | Follow-up (months) |
| Archik et al28 | 2017 | J Cancer Res Ther | 24 /M | II | R | No | Full ROM | 1.5 | ||
| Aycan et al6 | 2019 | Acta Orthop Traumatol Turc | 27 /F | C | Yes—after 14 years | MSTS 9/30 | 172 | |||
| 24 /M | C | No | MSTS 24/30 | 12 | ||||||
| Ferguson et al13 | 2015 | JHS E | 48 /F | II | R | Stabilisation with ECU | No | Full ROM | 24 | |
| 22 /F | III | R | Stabilisation with ECU | No | Full ROM | 24 | ||||
| Gracia et al14 | 2011 | Strategies Trauma Limb Reconstr | 56 /M | III | R | Prosthesis | No | Full ROM | 24 | |
| Jamshidi et al7 | 2018 | Med J Islam Repub Iran | 29 /M | II | C | No | MSTS 93.3% | 121 | ||
| 19 /F | II | C | No | MSTS 96.6% | 99 | |||||
| 65 /F | II | C | No | MSTS 93.3% | 54 | |||||
| 36 /F | II | C | No | MSTS 90% | 43 | |||||
| 27 /F | III | R | No | MSTS 83.3% | 67 | |||||
| 28 /M | III | R | (Yes—after the initial curettage) | MSTS 90% | 56 | |||||
| 29 /M | III | R | (Yes—after the initial curettage) | MSTS 93.9% | 72 | |||||
| 27 /F | III | R | No | MSTS 83.3% | 79 | |||||
| 29 /M | III | R | No | MSTS 93.3% | 25 | |||||
| Jeejesh et al8 | 2020 | Int J Surg Case Rep | 19 /F | II | C | No | Full ROM | 24 | ||
| Jones et al15 | 2020 | HAND(NY) | 29 /M | III | R | Prosthesis | No | Full ROM | 24 | |
| Kotrych et al16 | 2011 | JHS E | 35 /M | III | R | Prosthesis | No | DASH 42 | 24 | |
| McCarthy et al21 | 2017 | Clin Sarcoma Res | 39 /F | II | R | No | Preop | 54 | ||
| Jones and Graham7 | 2020 | Int J Surg Case Rep | 43 /M | III | R | Stabilisation with ECU | No | MSTS 25/30 | 10 | |
| 31 /F | III | R | stabilisation with ECU | No | MSTS 24/30 | 10 | ||||
| Kotrych et al18 | 2013 | Indian J Orthop | 43 /M | III | R | S-K with bone graft | No | Full ROM | 36 | |
| Papanastassiou et al9 | 2019 | HAND(NY) | 44 /F | R | No | MSTS 30/30 | 30 | |||
| 25 /F | R | Stabilisation with ECU | No | MSTS 29/30 | 108 | |||||
| 65 /M | R | No | MSTS 30/30 | 60 | ||||||
| 40 /F | III | R | No | MSTS 29/30 | 30 | |||||
| 37 /F | III | R | Stabilisation with ECU | No | MSTS 28/30 | 30 | ||||
| 24 /M | R | (Yes—after the initial curettage) | MSTS 23/30 | 30 | ||||||
| 24 /F | R | No | MSTS 29/30 | 60 | ||||||
| 28 /M | R | Stabilisation with ECU | (Yes-after the initial curettage) | MSTS 21/30 | 24 | |||||
| 44 /F | III | R | Stabilisation with ECU | No | MSTS 29/30 | 24 | ||||
| Park et al12 | 2014 | Skeletal Radiol | 35 /F | III | R | Yes—after 21 months | ||||
| Sanchez-Pareja et al22 | 2016 | Int J Surg Pathol | 35 /M | III | R | No | Preop | |||
| Thiounn et al19 | 2017 | Hand Surg Rehabil | 60 /F | III | R | Prosthesis and stabilisation with BR | No | DASH 40.9 | 18 | |
| 52 /M | III | R | Prosthesis and stabilisation with BR | No | DASH 42.5 | 18 | ||||
| Tsai et al20 | 2019 | JBJS Case Connect | 33 /M | II | R | S-K with bone graft | No | DASH 4.5 | 12 | |
| Vanni et al10 | 2012 | J Med Case Rep | 17 /M | II | C | No | Full ROM | 36 | ||
| von Borstel et al11 | 2017 | Skeletal Radiol | 29 /M | III | C | Yes—after 5 months | Preop | |||
| Zhan et al29 | 2016 | Mol Clin Oncol | II to III, 6 cases | R | No | |||||
BR, brachioradialis; C, curettage; DASH Score, The Disabilities of the Arm, Shoulder and Hand Score; ECU, extensor carpi ulnaris; MSTS, Musculoskeletal Tumor Society scoring system; R, resection; S-K, Sauvé-Kapandji.